Clinical Trial Update: Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing Lenvatinib plus tislelizumab versus Lenvatinib alone in hepatocellular carcinoma patients previously treated with anti-P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING